Know Cancer

or
forgot password

Reduced Intensity Conditioning Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies at High Risk for Transplant Related Mortality With Standard Transplantation


Phase 2
N/A
21 Years
Not Enrolling
Both
Acute Leukaemia, Chronic Disease, Leukemia, Myelodysplasia, Lymphoma

Thank you

Trial Information

Reduced Intensity Conditioning Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies at High Risk for Transplant Related Mortality With Standard Transplantation


Summary/Proposal: Reduced Intensity Hematopoietic Cell Transplantation for High-Risk
Relapsed Pediatric Hematologic Malignancies and Patients Ineligible for Standard
Transplantation We propose a phase II trial of reduced intensity conditioning with
Bu/Flu/ATG in pediatric patients with hematologic malignancies at high risk for transplant
related mortality with standard transplantation. Patients qualify based on organ system
dysfunction, active but stable infection, history of previous transplant, or late stage
disease. We plan to enroll 45 patients through the Pediatric Blood and Marrow transplant
Consortium (PBMTC) and anticipate that the outcome of the trial will pave the way for phase
II or III disease specific protocols addressing efficacy of the approach compared to
standard transplant approaches in better risk patients.

Hypothesis High risk pediatric hematologic malignancy patients ineligible for standard
myeloablative HCT undergoing reduced intensity conditioning (RIC) HCT can achieve a
sustained engraftment rate > 90% with a 100day TRM < 30% using either bone marrow or PBSC
from related or unrelated donors. High risk pediatric patients undergoing RIC-HCT using
related or unrelated cord blood can achieve a sustained engraftment rate >80% and a 100d TRM
<30%.

Rationale for Reduced Intensity Approaches in High Risk Patients There are a number
patient-specific risk factors associated with increased transplant related mortality. They
can be broadly placed into three categories: pretransplant organ system dysfunction, active
infections at the time of transplant, and degree of pretransplant therapy (previous
transplants, third or subsequent remission, etc.).

The primary objective of this study is to determine the likelihood of achieving sustained
donor engraftment using reduced intensity conditioning (fludarabine/busulfan/ATG) followed
by hematopoietic cell transplantation (HCT) with either cord blood, bone marrow or
peripheral blood stem cells (PBMTC) in pediatric patients with hematopoietic malignancies
who are at high risk of transplant related mortality (TRM) with myeloablative HCT. Patients
qualify based on organ system dysfunction, active but stable infection, history of previous
transplant or late stage disease. We plan to enroll 45 patients through the Pediatric Blood
and Marrow Transplant Consortium (PBMTC) and anticipate that the outcome of the trial will
pave the way for phase II or III disease specific protocols addressing efficacy of the
approach compared to standard transplant approaches in better risk patients.

Study procedures Patients receive their conditioning regimen consisting of fludarabine,
busulfan, and ATG and then receive their stem cell transplant. Patients receive
immunosuppression consisting of cyclosporine and mycophenolate mofetil. Patients with
persistent or progressive disease may receive donor lymphocyte infusion off protocol.


Inclusion Criteria:



1. Patients must be age 21 or younger and must have hematologic malignancies treatable
with allogeneic hematopoietic transplantation (acute and chronic leukemias,
myelodysplasia or lymphomas, see protocol for further details). Patients qualify for
this approach in four ways: 1) presence of organ system dysfunction or severe
systemic infections that significantly increase transplant related mortality with
standard myeloablative transplant regimens, 2) history of previous myeloablative
allogeneic or autologous transplantation, 3) currently in a third or higher CR
receiving an unrelated stem cell transplant, or 4) a combination of toxicities that
leads the investigator to feel that the child is at high risk (>50%) of TRM.
Patients eligible for inclusion based on consideration number 4 above cannot be
enrolled unless discussed with the study chair.

2. Organ system dysfunction: at least one of the following organ system dysfunction
criteria plus minimum organ function listed in exclusion criteria qualify a patient
for treatment on this protocol

1. Pulmonary: DLCO, FEV1 or TLC/FVC <60% predicted. Patients too young for PFTs
with suspected pulmonary toxicity should be assessed by a consulting
pulmonologist. If the pulmonologist judges the child to have moderate-severe
pulmonary disease they qualify for inclusion.

2. Renal: creatinine clearance <60ml/m/1.73m2

3. Hepatic: transaminases >4x normal or total bilirubin >2.0

4. Cardiac: all patients with suspected cardiac toxicity should undergo a cardiac
echo. If the shortening fraction (SF) is <25% a measurement of ejection
fraction must be obtained. Patients qualify for reduced intensity therapy if
the SF is <25% and the EF <50%.

3. Infections: Patients with responsive but unresolved invasive infections. These
infections may be fungal, bacterial or other opportunistic infections. Viral
infections do not meet this eligibility criteria.

4. Other patient groups at high risk for transplant related mortality: Patients with a
history of a prior allogeneic or autologous transplantation and patients who are in
CR3 or greater and receiving an unrelated stem cell transplant are also eligible for
this protocol. If the investigator feels that a patient has a combination of risk
factors that could increase their risk of transplant related mortality to >50% with
standard transplantation they may be eligible for inclusion, but such patients must
be reviewed with the protocol chairman prior to enrollment.

Exclusion Criteria:

1. Patients must be in a CR (<5% blasts on BM morphology, no active CNS disease, see
protocol) with the following exceptions:

1. AML may proceed with M2 marrow status (<20% blasts).

2. Lymphoma: residual disease must be responsive and non-bulky (<5cm largest
diameter).

3. Myelodysplasia: Patients with RA, and RAEB are eligible, but RAEB-IT patients
are only eligible if treated to <5% blasts (RA) with chemotherapy.

4. CML-BP must be treated to CR/CP2 to be eligible.

2. Females who are pregnant

3. Patients who are HIV positive or who have other progressive infections

4. Organ dysfunction: patients are ineligible for the following levels of severe organ
system dysfunction:

1. Cardiac: Ejection fraction <30%

2. Pulmonary: Receiving continuous supplementary oxygen or any of the following:
DLCO <30%, FVC/TLC < 30% or FEV1 <30%

3. Hepatic: patients will be excluded for hepatic synthetic dysfunction evidenced
by any of the following: prolongation of the prothrombin time with an INR >2.0,
total serum bilirubin >3, or transaminases >10x normal.

4. Renal: patients with a creatinine clearance <30ml/m/1.73m2 or who require
dialysis are not eligible

Donor Eligibility Criteria:

1. Related or unrelated donor who is a 6/6 HLA match at HLA-A, B, and DRB1 locus. 5/6
matches are acceptable with mismatches at class I alleles (A and B), but DRB1
mismatches are not allowed. Intermediate resolution typing of class I and high
resolution typing of class II alleles is required. (HLA-C and HLA-DQ matching is
encouraged, but not required with the ideal donor matching at 10/10 alleles.)

2. Unrelated cord blood may be used if matched at HLA-A, B and DRB1 at either 4/6, 5/6,
or 6/6 antigens. The minimum mononuclear cell dose required for eligibility is 3 x
107 mononuclear cells/kg recipient body weight (based on frozen cell dose). It is
strongly suggested that a back up unit of umbilical cord blood be reserved, though
not requested, in case of rejection.

Donors must pass required institutional and NMDP health and infectious disease screening.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of High Risk Pediatric Patients With Successful Sustained Donor Engraftments

Outcome Description:

Assessed donor engraftment in very high risk pediatric patients.

Outcome Time Frame:

24 months

Safety Issue:

Yes

Principal Investigator

Michael Pulsipher, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Primary Children's Medical Center

Authority:

United States: Institutional Review Board

Study ID:

HCI12073

NCT ID:

NCT00795132

Start Date:

April 2004

Completion Date:

July 2009

Related Keywords:

  • Acute Leukaemia
  • Chronic Disease
  • Leukemia
  • Myelodysplasia
  • Lymphoma
  • cancer
  • Hematologic Malignancies
  • Hematopoietic Cell Transplantation
  • Neoplasms
  • Chronic Disease
  • Leukemia
  • Lymphoma
  • Myelodysplastic Syndromes
  • Preleukemia
  • Hematologic Neoplasms

Name

Location

Primary Children's Medical CenterSalt Lake City, Utah  84113-1100